Abstract
Experimental studies have demonstrated that thalidomide, a drug developed as a sedative, has antitumoral properties. Its broad spectrum of actions besides its antiangiogenic potential, includes immunomodulatory properties, antiinflammatory actions and direct effect on tumor cells and their microenvironment. Multiple myeloma is so far the most responsive malignancy.
Keywords: angiogenesis, antiangiogenesis, multiple myeloma, thalidomide
Letters in Drug Design & Discovery
Title: Thalidomide as an Antiangiogenic Drug in the Treatment of Multiple Myeloma
Volume: 1 Issue: 2
Author(s): Domenico Ribatti and Angelo Vacca
Affiliation:
Keywords: angiogenesis, antiangiogenesis, multiple myeloma, thalidomide
Abstract: Experimental studies have demonstrated that thalidomide, a drug developed as a sedative, has antitumoral properties. Its broad spectrum of actions besides its antiangiogenic potential, includes immunomodulatory properties, antiinflammatory actions and direct effect on tumor cells and their microenvironment. Multiple myeloma is so far the most responsive malignancy.
Export Options
About this article
Cite this article as:
Ribatti Domenico and Vacca Angelo, Thalidomide as an Antiangiogenic Drug in the Treatment of Multiple Myeloma, Letters in Drug Design & Discovery 2004; 1 (2) . https://dx.doi.org/10.2174/1570180043485491
DOI https://dx.doi.org/10.2174/1570180043485491 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Role of Carrier Geometry in Overcoming Biological Barriers to Drug Delivery
Current Pharmaceutical Design New N’-Arylidene-2-[(4-Nitrophenyl)Piperazın-1-yl]Acetohydrazide Derivatives: Synthesis and Anticancer Activity Investigation
Letters in Drug Design & Discovery Fluorine-18 Labeled Amino Acids for Oncologic Imaging with Positron Emission Tomography
Current Topics in Medicinal Chemistry PREFACE
Anti-Cancer Agents in Medicinal Chemistry Transposons for Gene Therapy!
Current Gene Therapy Anti-VEGF Mediated Immunomodulatory Role of Phytochemicals: Scientific Exposition for Plausible HCC Treatment
Current Drug Targets Anticancer Metallotherapeutics in Preclinical Development
Current Medicinal Chemistry Histone Deacetylase Inhibitors in Cancer Therapy: New Compounds and Clinical Update of Benzamide-Type Agents
Current Topics in Medicinal Chemistry Preparation and Biodistribution of Technetium-99m-Labeled Bis- Misonidazole (MISO) as an Imaging Agent for Tumour Hypoxia
Medicinal Chemistry Conference Report (The XVth International Symposium of Brain Edema and Cellular Injury)
CNS & Neurological Disorders - Drug Targets Novel Targeting of Apoptosis Pathways for Prostate Cancer Therapy
Current Cancer Drug Targets Preventive and Protective Roles of Dietary Nrf2 Activators Against Central Nervous System Diseases
CNS & Neurological Disorders - Drug Targets Neuropathic Pain and Lung Delivery of Nanoparticulate Drugs: An Emerging Novel Therapeutic Strategy
CNS & Neurological Disorders - Drug Targets Gamma Linolenic Acid: An Antiinflammatory Omega-6 Fatty Acid
Current Pharmaceutical Biotechnology Presence of Intratumoral Stem Cells in Breast Cancer Patients with or without BRCA Germline Mutations
Current Cancer Drug Targets The MCM Complex: Its Role in DNA Replication and Implications for Cancer Therapy
Current Cancer Drug Targets The Pathophysiological Role of PEDF in Bone Diseases
Current Molecular Medicine Macrophage Derived Cystatin B/Cathepsin B in HIV Replication and Neuropathogenesis
Current HIV Research Editorial [Hot Topic:Angiogenesis Agents(Executive Editor: Cezary Marcinkiewicz)]
Current Pharmaceutical Design Targeting Chk2 Kinase: Molecular Interaction Maps and Therapeutic Rationale
Current Pharmaceutical Design